Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 3/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19886124 | 0.89 | CA12 (0.41) | CA12CA1CA2CA9CYP2C9 | |
| SCHEMBL32669116 | 0.77 | NOTUM (0.40) | MAPK1 | |
| SCHEMBL19556559 | 0.71 | POLB (0.35) | CA12CA1CA2CA9PDE1B | |
| Lithium SCHEMBL31704760 | 0.70 | POLB (0.34) | CA12CA1CA2CA9PDE1B | |
| SCHEMBL24323731 | 0.68 | F2R (0.38) | MAPK1 | |
| SCHEMBL13638746 | 0.66 | DAO (0.31) | DAO | |
| SCHEMBL32669097 | 0.65 | CA12 (0.39) | CA12CA1CA2CA9CYP2C9 | |
| SCHEMBL14334386 | 0.64 | DAO (0.33) | PDE1BDAO | |
| SCHEMBL14334355 | 0.64 | DAO (0.40) | PDE1BDAO | |
| SCHEMBL31705029 | 0.64 | PDE4B (0.43) | HDAC4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CA12 4329/4885CA1 4795/4885CA2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.